Investment Thesis
Kraig Biocraft Laboratories faces critical financial distress with zero revenue generation, negative $8.0M stockholders' equity, and only approximately 12 months of cash runway at current burn rates. The combination of persistent operating losses of $3.6M annually, negative operating cash flow, and technical insolvency indicates high probability of restructuring or liquidation without immediate operational turnaround.
Strengths
- Modest long-term debt of $8.8K limits leverage burden and provides restructuring flexibility
- Maintains $1.8M in cash reserves providing near-term operational window for strategic alternatives
- Non-zero asset base of $2.6M offers some liquidation value floor
Risks
- Zero revenue generation indicates non-operational status with no documented path to market validation or profitability
- Negative stockholders' equity of -$8.0M combined with 0.18x current ratio signals imminent insolvency and bankruptcy risk
- Negative operating cash flow of -$1.8M annually with depleting reserves creates approximately 12-month operational runway before capital depletion
Key Metrics to Watch
- Quarterly revenue generation - any revenue would indicate operational progress and market validation
- Monthly operating cash burn rate - critical for determining remaining cash runway and restructuring timeline
- Stockholders' equity trend - movement toward positive territory would signal stabilization or successful capital injection
Financial Metrics
Revenue
0.0
Net Income
-3.6M
EPS (Diluted)
$0.00
Free Cash Flow
-1.8M
Total Assets
2.6M
Cash
1.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-141.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.18x
Quick Ratio
0.18x
Debt/Equity
N/A
Debt/Assets
411.8%
Interest Coverage
-21.92x
Long-term Debt
8.8K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T00:33:29.418966 |
Data as of: 2025-12-31 |
Powered by Claude AI